Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/8115
Full metadata record
DC FieldValue
dc.contributor.authorVallve, Maria de Lourdes Farre
dc.contributor.authorBittencourt, Achilea Candida Lisboa
dc.contributor.authorSantos, Gilvanéia Silva
dc.contributor.authorAlmeida, A.
dc.contributor.authorSilva, A. C.
dc.contributor.authorDecanine, Daniele
dc.contributor.authorSoares, G. M.
dc.contributor.authorAlcantara, Luiz Carlos Júnior
dc.contributor.authorVan Dooren, Sonia
dc.contributor.authorCastro Filho, Bernardo Galvão
dc.contributor.authorVandamme, Anne-Mieke
dc.contributor.authorVan Weyenbergh, Johan Jozef Rosa Maria
dc.date.accessioned2014-08-01T15:59:01Z
dc.date.available2014-08-01T15:59:01Z
dc.date.issued2007
dc.identifier.citationVALLVE, M. L. F. et al. Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. Journal of Leukocyte Biology, v. 83, n. 1, p. 220-222, 2008.
dc.identifier.issn0741-5400
dc.identifier.urihttps://www.arca.fiocruz.br/handle/icict/8115
dc.language.isoeng
dc.publisherSociety for Leukocyte Biology
dc.rightsrestricted access
dc.titleFas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia.
dc.typeArticle
dc.identifier.doi10.1189/jlb.0407198
dc.description.abstractenFas (TNFRSF6/Apo-1/CD95) is a type I transmembrane receptor, which mediates apoptosis. Fas gene mutations, aberrant transcripts, and abundant expression of Fas have been reported in adult T cell leukemia (ATL). To further elucidate the role of Fas in ATL pathogenesis, we investigated whether the –670 FAS promoter A/G polymorphism (STAT1- binding site) might contribute to susceptibility and clinical outcome in ATL. Thirty-one patients with ATL, 33 healthy, human T lymphotropic virus type 1-infected individuals, and 70 healthy, uninfected controls were genotyped for the FAS –670 polymorphism by PCR-restriction fragment-length polymorphism. The AA genotype was significantly over-represented in ATL patients in comparison with healthy controls (P 0.006), as well as asymptomatics (P 0.037), corresponding to an odds ratio (OR) of 3.79 [95% confidence intervals (CI; 1.28–11.41)] and 4.58 [95% CI (1.13–20.03)], respectively. The AA group also comprised significantly more aggressive (acute and lymphoma) clinical subtypes [P 0.012; OR 8.40; 95% CI (1.60–44.12)]. In addition, we observed a statistically significant association between GG genotype and survival (log rank test, P 0.032). Finally, IFN- -induced but not basal FAS mRNA levels were increased significantly (P 0.049) in PBMCs from AA versus GG individuals, demonstrating the IFNdependent functionality of the –670 polymorphism. In conclusion, our results demonstrate that a functional Fas promoter polymorphism is significantly associated to susceptibility, clinical manifestation, and survival in ATL.
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório de Imunorregulação e Microbiologia. Salvador, BA, Brasil
dc.creator.affilliationHospital Universitário Professor Edgard Santos. HUPES. Salvador, BA, Brasil
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório de Imunorregulação e Microbiologia. Salvador, BA, Brasil
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório de Imunorregulação e Microbiologia. Salvador, BA, Brasil
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório de Imunorregulação e Microbiologia. Salvador, BA, Brasil
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório de Imunorregulação e Microbiologia. Salvador, BA, Brasil
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório de Imunorregulação e Microbiologia. Salvador, BA, Brasil
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil
dc.creator.affilliationRega Institute. Clinical and Epidemiological Virology. Leuven, Belgium
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil
dc.creator.affilliationRega Institute. Clinical and Epidemiological Virology. Leuven, Belgium
dc.creator.affilliationInstituto de Investigação em Imunologia. iii–Millenium Institute. São Paulo, SP, Brasil
dc.subject.enTNFRSF6
dc.subject.enATL
dc.subject.enSTAT1
dc.subject.enHTLV-1
dc.subject.enApoptosis
dc.subject.decsAntígenos CD95/genética
dc.subject.decsPredisposição Genética para Doença/genética
dc.subject.decsLeucemia de Células T/genética
dc.subject.decsPolimorfismo de Nucleotídeo Único/genética
dc.subject.decsRegiões Promotoras Genéticas/genética
dc.subject.decsAntígenos CD95/imunologia
dc.subject.decsSeguimentos
dc.subject.decsGenótipo
dc.subject.decsInfecções por HTLV-I/imunologia
dc.subject.decsHumanos
dc.subject.decsInterferon gama/farmacologia
dc.subject.decsLeucemia de Células T/diagnóstico
dc.subject.decsLeucócitos Mononucleares/efeitos de drogas
dc.subject.decsRNA Mensageiro/genética
dc.subject.decsFatores de Risco
dc.subject.decsTaxa de Sobrevida
Appears in Collections:BA - IGM - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
Farre L. Fas-670 promoter....pdf119.31 kBAdobe PDFView/Open



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.